NasdaqCM - Delayed Quote • USD
Atossa Therapeutics, Inc. (ATOS)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 7:50 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | -0.06 | -0.06 | -0.27 | -0.3 |
| Low Estimate | -0.07 | -0.07 | -0.31 | -0.35 |
| High Estimate | -0.06 | -0.06 | -0.24 | -0.26 |
| Year Ago EPS | -0.05 | -0.08 | -0.24 | -0.27 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.06 | -0.06 | -0.07 | -0.06 |
| EPS Actual | -0.05 | -0.08 | -0.05 | -0.09 |
| Difference | 0.01 | -0.02 | 0.02 | -0.03 |
| Surprise % | 16.70% | -33.30% | 28.60% | -50.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.06 | -0.06 | -0.27 | -0.3 |
| 7 Days Ago | -0.06 | -0.06 | -0.27 | -0.3 |
| 30 Days Ago | -0.06 | -0.06 | -0.26 | -0.32 |
| 60 Days Ago | -0.06 | -0.06 | -0.26 | -0.32 |
| 90 Days Ago | -0.06 | -0.06 | -0.25 | -0.28 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ATOS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -20.00% | -- | -- | 0.80% |
| Next Qtr. | 25.00% | -- | -- | 9.60% |
| Current Year | -12.50% | -- | -- | 4.50% |
| Next Year | -11.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/16/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/2/2024 |
| Initiated | HC Wainwright & Co.: Buy | 2/12/2024 |
| Initiated | Cantor Fitzgerald: Overweight | 9/8/2023 |
| Initiated | Ascendiant Capital: Buy | 9/17/2020 |
| Upgrade | Maxim Group: Hold to Buy | 12/18/2019 |
Related Tickers
SLS SELLAS Life Sciences Group, Inc.
1.5200
+7.80%
OCGN Ocugen, Inc.
1.3200
-8.33%
JAGX Jaguar Health, Inc.
0.1771
+7.40%
CTXR Citius Pharmaceuticals, Inc.
0.8055
-1.31%
CADL Candel Therapeutics, Inc.
5.46
+0.37%
ICU SeaStar Medical Holding Corporation
0.5400
-22.79%
EYEN Eyenovia, Inc.
0.5309
-1.56%
AKBA Akebia Therapeutics, Inc.
1.3900
0.00%
VERU Veru Inc.
1.4200
+22.41%
OCEA Ocean Biomedical, Inc.
1.8750
+5.04%